Skip to main content

CANALOSOMA DE KV1.5: PAPEL DE LGI1-4 Y SIG-1R. CONSECUENCIAS FARMACOLOGICAS

SAF2013-45800-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2013
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Dream-modulators for dreaming of novel drugs for neurodegenerative diseases

  • Cercós, Pilar
  • Peraza, Diego A.
  • Prieto, Ángela
  • González, Teresa
  • Mellström, Britt
  • García-López, M. Teresa
  • Herranz, Rosario
  • Martín-Martínez, Mercedes
  • Valenzuela, Carmen
  • Naranjo, José Ramón
  • Gutiérrez-Rodríguez, Marta
Resumen del póster presentado al Spanish-Italian Medicinal Chemistry Congress, celebrado en Barcelona (España) del 12 al 15 de julio de 2015., Altered neuronal calcium homeostasis and early compensatory changes in transcriptional programs are common features of many neurodegenerative pathologies including Alzheimer's disease, Down syndrome and Huntington's disease. DREAM (Downstream Regulatory Element Antagonist Modulator, also known as calsenilin or KChIP-3 (potassium channel interacting protein-3), is a multifunctional calcium binding protein that controls the expression level and/or the activity of several proteins related to calcium homeostasis, neuronal excitability and neuronal survival. This protein is widely expressed in the brain and, depending on the cell type and physiological conditions, shows multiple subcellular localizations, in the nucleus, cytosol or cell membrane. The interest in DREAM is based on its key role in the regulation of intracellular calcium levels. As a calcium-dependent transcriptional repressor, DREAM is a master regulator of activity-dependent gene expression and controls genes important for calcium homeostasis. As an auxiliary protein in the plasma membrane, DREAM interacts with and regulates the gating of Kv4 potassium channels, L- and T-type voltage-dependent calcium channels and NMDA receptors. These findings suggest that DREAM could be a novel and versatile target for therapeutic intervention in neurodegeneration and that molecules able to bind to DREAM and modulate its physiological functions could be candidates for drugs to treat neurodegenerative diseases. Moreover, up to now, only two DREAMbinding molecules have been identified. In this communication we report the rational design and the synthesis of novel DREAM-binding molecules and their effects on the modulation of DREAM/protein interactions., This work was supported by Ministerio de Economia y Competitividad (SAF2012-32209 and SAF2013-45800-R) CSIC (201280E096-PIE) and Instituto de Salud Carlos III/CIBERNED . P. Cercós and A. Prieto hold a FPI fellowship from the Spanish Ministerio de Ciencia e Innovación. T. Gonzalez holds a Ramón y Cajal contract. This work has been awarded with the Janssen Cilag Award for Young Researchers from the Sociedad Española de Química Terapéutica (SEQT)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Fludarabine inhibits Kv1.3 currents in human B lymphocytes

  • Vera-Zambrano, Alba
  • Peraza, Diego A.
  • Valenzuela, Carmen
  • Pérez-Chacón, Gema
  • González, Teresa
Resumen del trabajo presentado al 5th Symposium on Biomedical Research: "Advances and Perspectives In Pharmacology, Drug Toxicity and Pharmacogenetics", celebrado en Madrid del 15 al 16 de marzo de 2018., [Introduction]:Fludarabine (F-ara-A) is a purine analogue commonly used in the treatment of indolent B cell malignancies that interferes with different aspects of DNA and RNA synthesis. KV1.3 potassium channels are membrane proteins involved in the control of K+ homeostasis and in the maintenance of the resting potential of the cell, thus controlling signalling events, proliferation and apoptosis in lymphocytes. The aim of this study was to determine if F-ara-A modulates KV currents in human B lymphocytes. [Material and methods]: We assessed the expression, the activity and the effect of F-ara-A on the KV1.3 channel in BL2 and Dana B cell lines. Currents were registered by whole-cell patch-clamp. Statistical significance was determined by t-Student test or by nonparametric Mann-Whitney test. [Results]: We show that KV1.3 is expressed in both BL2 and Dana B cell lines, although total KV1.3 levels were higher in BL2 compared to those in Dana cells. However, KV currents in the plasma membrane were similar in both cell lines. These KV currents were abrogated by the specific KV1.3 channel inhibitor PAP-1, indicating that most KV currents in these B cell lines are controlled by KV1.3. F-ara-A (3.5 μM), a concentration similar to that achieved in the plasma of fludarabine phosphate-treated patients (3 μM), inhibited KV1.3 currents by 61±6.3% and 52.3±6.3% in BL2 and Dana B cells, respectively. The inhibitory effect of F-ara-A was concentration dependent and showed an IC50 value of 0.36±0.04 μM and a nH value of 1.07±0.15 in BL2 cells and 0.34±0.13 μM (IC50) and 0.77±0.11 (nH) in Dana cells. This inhibitory effect of F-ara-A on the activity of plasma membrane KV1.3 was observed in these cells irrespective of their cytotoxic effect. F-ara-A had no effect on heterologously expressed KV1.3 channels, suggesting an indirect mechanism of inhibition. [Conclusions]: Fludarabine (F-ara-A), a chemotherapeutic drug extensively used in clinics, strongly inhibits KV1.3 currents in B lymphoma and lymphoblastoid cells. Although this inhibitory activity is not sufficient to induce cell death, it might still contribute to the cytotoxic effect of the drug., This study was supported by MINECO (SAF2013-45800-R, SAF2016-75021-R, RD12/0042/0019, CB/11/00222) and ISCIII (PI12/01135 and PI16/00895)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

KV1.3 channel inhibition by indolic compounds in chronic lymphocytic leukemia cells

  • Baena-Nuevo, M.
  • Vera-Zambrano, Alba
  • Martínez-Laperche, Carolina
  • Muñoz-Calleja, Cecilia
  • Buño, Ismael
  • Zapata, Juan M.
  • Pérez-Chacón, Gema
  • González, Teresa
Resumen del trabajo presentado al 5th Symposium on Biomedical Research: "Advances and Perspectives In Pharmacology, Drug Toxicity and Pharmacogenetics", celebrado en Madrid del 15 al 16 de marzo de 2018., [Introduction]: Chronic lymphocytic leukemia (CLL) is the most common leukemia in western countries and it is based on B cell clonal expansion. This disease has no cure and the appearance of pharmacological resistance is very common. We have previously identified indole-3-carbinol (I3C) and its main metabolite, 3,3’-diindolylmethane (DIM), as active compounds with pharmacological activity against CLL. KV1.3 potassium channels are involved in B and T cells function controlling plasmatic membrane potential, Ca2+ entry and cellular proliferation. Therefore, these channels could be a new therapeutic target against CLL. Here, we have analysed if these indolic compounds can act, in part, by modulating the KV1.3 function., [Material and Methods]: we assessed the activity and effect of the indolic compounds on KV1.3 channels in CLL cells that are either sensitive or resistant to I3C cytotoxicity. Currents were registered by whole-cell patch-clamp. Statistical significance was determined by t-Student test or by nonparametric Mann-Whitney test., [Results]: The KV1.3 current magnitude on CLL cells correlated with their sensitivity to the cytotoxic effect of I3C; I3C resistant CLL (IR-CLL) cells exhibiting ≈2.5-fold higher KV1.3 current amplitude than sensitive (IS-CLL) cells. Both I3C and DIM inhibited KV1.3 current in CLL cells, DIM being ≈4-fold more potent than the parent compound. However, a non-cytotoxic compound, indole-3-carboxylic acid (I3CA), did not inhibit the KV1.3 current., [Conclusions]: IR-CLL cells exhibit greater KV1.3 current magnitude than IS-CLL cells, which can be due to the existence of different canalosomes in these cells. The KV1.3 inhibitory effect of the indolic compounds tested, correlates with their cytotoxic effect on CLL cells. Our results suggest that KV1.3 channel could be involved in CLL cells pharmacological resistance mechanisms and its inhibition could be part of the cytotoxic effect of I3C and DIM, which open new venues to the treatment of this disease., This study was supported by MINECO (SAF2013-45800-R, SAF2016-75021-R, RD12/0042/0019, CB/11/00222) and ISCIII (PI12/01135 and PI16/00895)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Effects of n-3, n-6 PUFAs and their derivatives on KV7.1/KCNE1 channels

  • Cruz, Alicia de la
  • Moreno, Cristina
  • Peraza, Diego A.
  • Valenzuela, Carmen
Resumen del trabajo presentado al VI Meeting de la Red Española de Canales Ióniocs (RECI), celebrado en Santiago de Compostela del 6 al 8 de septiembre de 2017., Voltage-dependent potassium channels are spanning-membrane integral proteins involved in several and diverse physiological and pathological processes such as immune response or cardiovascular function. KV7.1 channel with the KCNE1 regulatory subunit form one of the most important current of the repolarization phase of the cardiac action potential (IKs). We analyzed, using the patch-clamp technique, the acute and chronic exposition of polyunsaturated fatty acids (PUFAs), DHA and AA, in KV7.1/KCNE1 channels expressed in COS-7 cells. Acute DHA and AA exposition increased the magnitude of KV7.1/KCNE1 currents. DHA but not AA slowed the activation kinetics. However, both PUFAs accelerated the deactivation kinetics. Chronic exposition to these compounds did not modify the magnitude of the currents. However, DHA shifted the activation curve toward more negative membrane potentials and accelerated the activation and deactivation kinetics of the channels. On the contrary, AA slowed the activation whereas it accelerated the deactivation process. PUFAs effects on KV7.1/KCNE1 channels depends on both the compound’s chemical nature, n-3 or n-6 PUFAs, as well as the time of exposure, which might be acute or chronic. It has been described that enriched PUFAs diet has anti-inflammatory properties. Moreover, n-3 or n-6 PUFAs lipidderived mediators such as lipoxins and resolvins (which levels are increased by the consumption of aspirin), have been emerged as potent anti-inflammatory agents that promote the resolution phase of the inflammation process. Ion channels, and specially potassium ion channels, play an essential role in macrophages physiology. Accordingly, we also studied the lipid-derived mediators effects on both bone marrow derived macrophages (BMDM), which LPSdependent activation are related with the increased of KV1.3/KV1.5 expression, and in KV7.1/KCNE1 channels where the PUFAs effects have been studied. Lipoxins, but not resolvins, could reverse the LPS-activated macrophages. However, resolvins KV7.1/KCNE1 block were much more potent., Funded by SAF2013-45800-R, SAF2016-75021-R, BFU2014-54928-R and CIBERCV (FIS CB/11/00222)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

D242N, a KV7.1 LQTS mutation uncovers a key residue for IKs voltage dependence

  • Moreno, Cristina
  • Oliveras, Anna
  • Bartolucci, Chiara
  • Muñoz, Carmen
  • Cruz, Alicia de la
  • Peraza, Diego A.
  • Gimeno, Juan R.
  • Martín-Martínez, Mercedes
  • Severi, Stefano
  • Felipe, Antonio
  • Lambiase, Pier
  • González, Teresa
  • Valenzuela, Carmen
Resumen del trabajo presentado al VI Meeting de la Red Española de Canales Ióniocs (RECI), celebrado en Santiago de Compostela del 6 al 8 de septiembre de 2017., KV7.1 and KCNE1 co-assemble to give rise to the IKs current, one of the most important repolarizing currents of the cardiac action potential. Its relevance is underscored by the identification of more than 500 mutations in KV7.1 and, at least, 36 in KCNE1, that cause Long QT Syndrome (LQTS). The aim of this study was to characterize the biophysical and cellular consequences of the D242N KV7.1 mutation associated with the LQTS. The mutation is located in the S4 transmembrane segment, within the voltage sensor of the KV7.1 channel, disrupting the conserved charge balance of this region. Perforated patch-clamp experiments show that, unexpectedly, the mutation did not disrupt the voltagedependent activation but it removed the inactivation and slowed the activation kinetics of D242N KV7.1 channels. Biotinylation of cell-surface protein and co-immunoprecipitation experiments revealed that neither plasma membrane targeting nor co-assembly between KV7.1 and KCNE1 was altered by the mutation. However, the association of D242N KV7.1 with KCNE1 strongly shifted the voltage dependence of activation to more depolarized potentials (+50mV), hindering IKs current at physiologically relevant membrane potentials. Both functional and computational analysis suggest that the clinical phenotype of the LQTS patients carrying the D242N mutation is due to impaired action potential adaptation to exercise and, in particular, to increase in heart rate. Moreover, our data identify D242 aminoacidic position as a potential residue involved in the KCNE1-mediated regulation of the voltage dependence of activation of the KV7.1 channel., Funded by SAF2013-45800-R, SAF2016-75021-R, BFU2014-54928-R and CIBERCV (FIS CB/11/00222)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Identification of IQM-266, a novel DREAM ligand that modulates Kv4 currents

  • Peraza, Diego A.
  • Cercós, Pilar
  • Miaja, Pablo
  • Merinero, Yaiza G.
  • Lagartera, Laura
  • Socuéllamos, Paula G.
  • Izquierdo García, Carolina
  • Sánchez, Sara A.
  • López-Hurtado, Alejandro
  • Martín-Martínez, Mercedes
  • Olivos-Oré, Luis Alcides
  • Naranjo, José Ramón
  • Artalejo, Antonio R.
  • Gutiérrez-Rodríguez, Marta
  • Valenzuela, Carmen
Resumen del trabajo presentado al VII Congreso Red Española Canales Iónicos: Symposium 6: Drug Discovery and ion channel Pharmacology, celebrado en Cáceres del 15 al 17 de mayo de 2019., Funded by BFU2015-67284-R (to MG-R), SAF2014-53412-R and SAF2017-89554-R (to JN), SAF2013-45800-R, SAF2016-75021-R (to CV), SAF2015-66275-C2-2-R (to MM-M); UCM grant: PR75/18-21593 (to AA); and CSIC grants: PIE 201820E104 (to CV) and 201880E109 (to MG-R and MM-M)., Peer Reviewed